Medeor Therapeutics, Inc.

Medeor Therapeutics, Inc. is a biotechnology and pharmaceutical company, with a vision to revolutionize the field of transplantation through their pioneering immunotherapy. The company, founded in 2012, focuses on improving the lives of transplant patients and individuals with immune and hematological diseases. Medeor aims to achieve lasting organ tolerance, minimizing the need for immunosuppressant drugs. In addition, the company plans to address unmet needs in hematologic and rare diseases. With 20 years of research and development, Medeor has now advanced to phase 3 of a groundbreaking transplant program. Notably, they have reported no organ loss due to acute rejection, showcasing the potential of their approach.

The latest investment of $18.80M in Medeor was a grant investment received on 22 January 2018 from the California Institute for Regenerative Medicine. This infusion of funds bolsters their endeavors to bring their innovative immunotherapy to the market and makes strides in addressing critical unmet medical needs.

Medeor's journey, which began at Stanford University, has evolved into a promising biomedical platform. Their efforts have led to pivotal immunotherapy clinical trials with compelling results, positioning the company at the forefront of redefining transplantation. With their steadfast focus and significant progress, Medeor Therapeutics, Inc. presents an intriguing opportunity for potential investors to support a transformative force in the biotechnology and pharmaceutical industries.